secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001104659-24-112053
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 1.02, 2.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome acquires full ownership of ROR1 ADC assets from Zentalis for 1.8M shares plus $5M milestone
--------------------------------------------------------------------------------

- Issued 1,805,502 shares of common stock to Zentalis as partial consideration for the asset purchase.
- Obligated to pay $5M cash upon achievement of a developmental milestone; prior License Agreement terminated.
- Standstill restrictions on Zentalis for one year; lockup on selling >50% of shares for six months.
- Immunome to file resale registration statement within 30 days for shares issued to Zentalis.
- Asset purchase includes ROR1 antibody-drug conjugate platform and related intellectual property.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924112053/0001104659-24-112053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924112053/tm2426946d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-112053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer